Study: NCT00718718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136 100 mg
Description: CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136 100 mg
Description: CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136 100 mg
Description: CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136 100 mg
Description: CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136 100 mg
Description: CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136 50 mg
Description: CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136 25 mg
Description: CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be adminstered subcutaneously as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be adminstered subcutaneously as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be adminstered subcutaneously as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be adminstered subcutaneously as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be adminstered subcutaneously as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be adminstered subcutaneously as per the appropriate randomized arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable dose of methotrexate will be maintained through Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable dose of methotrexate will be maintained through Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable dose of methotrexate will be maintained through Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable dose of methotrexate will be maintained through Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable dose of methotrexate will be maintained through Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable dose of methotrexate will be maintained through Week 24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Stable dose of methotrexate will be maintained through Week 24.